Evaluation of Aprepitant as Prophylactic Antiemetics of Highly Emetogenic Chemotherapy
نویسندگان
چکیده
منابع مشابه
The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India
Background. The efficacy, safety, and cost benefit of olanzapine (OLN) when compared to aprepitant (APR) in the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) were evaluated. Methods. A prospective pilot study was done in chemotherapy-naive patients receiving HEC to compare OLN versus APR along with palonosetron and dexam...
متن کاملEfficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
AIMS AND BACKGROUND To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). METHODS Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and...
متن کاملFosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
INTRODUCTION The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed as an intravenous prodrug of aprepitant. AIMS To update the evidence underlying the use of fosaprepitant to prevent CINV. ...
متن کاملAntiemetics in cancer chemotherapy.
Nausea and vomiting induced by several cancer chemotherapy agents is often the most distressing side effect of treatment. The mechanisms are quite complex. The vomiting center in the reticular formation can be stimulated by either afferent stimuli from the gastrointestinal tract or by the chemoreceptor trigger zone (e1Z). The latter is probably the primary site for emetic activity of most cance...
متن کاملA randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.
Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of hematological malignancies. Although aprepitant, an NK1 receptor antagonist, has been shown to control CINV in highly emetogenic therapies for solid tumors, the antiemetic effect of this agent in hematological chemotherapies is not well established. In this randomized controlled trial, we examined the add...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
سال: 2013
ISSN: 1346-342X,1882-1499
DOI: 10.5649/jjphcs.39.245